Gastroenterology

Jacqueline Khalil, DO, reviews findings from 2 studies about the association between hormone replacement therapy with IBS and gastric motility disorders.

ChatGPT may provide helpful information around gastroparesis, IBS and celiac disease diets, according to findings from a new study.

Braden Kuo, MD, explains how GLP-1 RA use increases residual gastric content but does not significantly impact negative endoscopy outcomes.

Lacy explains the potential value of an ambulatory wireless patch test for identifying unique gastric activity patterns and individualizing patient care.

Fass reviews findings from a post hoc analysis of a phase 2 trial suggesting the value of vonoprazan as an on-demand NERD treatment.

New ACG 2024 data show patients with both IBD and vitamin D deficiency face longer, more expensive hospital stays, as well as risk of colectomy.

Ritter reviews findings from 2 real-world studies supporting the safety and efficacy of live-jslm (Rebyota) for recurrent C Diff infection.

New late-breaking ACG 2024 data supports AIMS65 as a risk factor tool for patients undergoing anticoagulant reversal.

The CRAC channel inhibitor zegocractin significantly improved acute pancreatitis patients' time to eating food and risk of respiratory failure in new data.

Post hoc analyses from the LIBERTY trials support infliximab as either a monotherapy or combination therapy for ulcerative colitis or Crohn's disease.

Lacy explains limitations to current motility measurements and reviews findings from his study exploring the potential of a wireless motility patch system.

Test your knowledge of the 2024 American College of Gastroenterology acute pancreatitis diagnosis and management guidelines with this clinical quiz!

Test your knowledge of the 2024 American College of Gastroenterology H. pylori management guidelines with this clinical quiz!

Patients with greater HADS-D scores were less likely to achieve symptomatic response or remission with a 2-step dietary intervention for IBS.

Adherence to an adapted low FODMAP diet and its impact on IBS symptoms were not affected based on the presence of fibromyalgia.

Patients with IBD or arthritis were not found to be at a significantly higher risk of serious infection with a biosimilar versus originator of the common drugs.

Linaclotide was safe and effective for patients with chronic constipation and IBS with constipation who switched after non-response to magnesium oxide.

In focus groups, patients indicated symptom bothersomeness and life interference should be included in clinical evaluation for disorders of gut-brain interaction.

Patients taking GLP-1 RAs were more likely to show food retention and inadequate bowel preparation, even when the medications were held before the procedure.

The approval is based on findings from BLUE-C, where Cologuard Plus demonstrated sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity.

This month in review spotlights recent GI pipeline news, new research about IBS and other gastroenterological conditions, and coverage from the 2024 GHAPP conference.

Compared to those without SLD, patients with MASLD, MetALD, and other combination etiology had a greater risk of developing liver and gastrointestinal cancers.

Crimaldi reviews key considerations for the diagnosis and management of bowel ischemia, diverticulitis, and small bowel obstructions in GI inpatients.

Subgroup analyses revealed FMT delivered through endoscopy, nasojejunal tube, and rectal enema had a greater impact on clinical response, symptom improvement, and quality of life.

Oral vitamin D improves vitamin D status and quality of life in IBS patients but does not significantly reduce symptom severity, a new study suggests.

A new study finds causal links between schizophrenia and MDD on IBS, highlighting the need for integrated care addressing both psychiatric and gastrointestinal symptoms.

The FDA declined to approve the NDA for tradipitant for the treatment of symptoms of gastroparesis, suggesting that Vanda conduct additional studies.

Banty discusses recent advancements in the ulcerative colitis and Crohn disease treatment landscapes, explaining how to navigate the growing number of treatment options.

Richards describes the utility of different NITs in primary and specialty care for risk-stratifying patients with MASH and fibrosis.